Please login to the form below
constipation
This page shows the latest constipation news and features for those working in and with pharma, biotech and healthcare.
Karuna’s shares spike on schizophrenia drug data
dose. The most common side effects were constipation, nausea, dry mouth, dyspepsia and vomiting.
Latest news
-
Ardelyx gets second kidney disease trial win for tenapanor
Shares in Ardelyx rocketed 72% on the back of the new study on the prospect of a second indication for tenapanor to follow constipation associated with IBS, which is under review
-
China approves Ironwood Pharma’s IBS treatment
Approval by China’s NMPA for adults with irritable bowel syndrome with constipation (IBS-C) opens up the country's huge market to the treatment. ... This approval is incredibly important as it brings a new option to treat some of the bothersome
-
Shire bags US approval for constipation drug Motegrity
Approval is boost as Takeda takeover nears completion. Shire has the US approval it needs for Motegrity, a drug for chronic idiopathic constipation (CIC) that will compete with drugs like
-
Immunology keeps Shire figures solid as Takeda takeover nears
HAE, prucalopride (SHP555) for chronic idiopathic constipation, and calaspargase pegol (SHP663) for the treatment of acute lymphoblastic leukaemia (ALL).
-
Mallinckrodt pays $1.2bn for Sucampo Pharma
As 2017 drew to a close, Mallinckrodt signed a deal to buy Sucampo Pharma of the US - and its constipation drug Amitizia - for $1.2bn. ... Amitizia is the prize asset in the deal, with FDA approvals in hand for three indications - chronic idiopathic
More from news
Approximately 8 fully matching, plus 67 partially matching documents found.
Latest Intelligence
-
Case study: What we're made of
If we don’t drink enough water, it can lead to headaches, constipation, tiredness and more serious problems, such as urinary infections and kidney disease.
-
Erectile dysfunction, constipation, vaginal dryness and other laughing matters
Diarrhoea, constipation, flatulence, leaky bladder, vaginal dryness - it’s all fertile territory.
-
Taking a lean and careful approach
His pioneering research culminated in the drug, Trulance, which has received FDA approval and is being used to treat irritable bowel syndrome and chronic constipation.
-
Deal Watch March 2016
$110. AstraZeneca/ Kyowa Hakko Kirin. Opioid-induced constipation – Moventig. Licence. $70.
-
Oral biologics delivery still elusive
years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Ironwood appoints Edward Owens to board
irritable bowel syndrome and constipation.
-
Norgine’s Karen Hockey promoted to head of global marketing
Appointment follows nearly two years as global brand manager for constipation treatment Movicol. ... Hockey's promotion comes after nearly two years as global brand manager for constipation treatment Movicol since joining Norgine in 2011.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- AZ/Oxford University vaccine shows 82.4% efficacy with extended dosing schedule
- Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine
- Sinovac’s COVID-19 vaccine appears safe in older adults
- bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin
- Pfizer, BioNTech temporarily slow down shipments of COVID-19 vaccine to EU
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- UK introduces Rare Diseases Framework to improve the lives of people with rare diseases
- Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- Merck to acquire Pandion Therapeutics for $1.85bn
- bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
PMHub
Madmicrobe Studios
MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...
Latest intelligence
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- What key things do you need to remember to reach patients living with Alzheimer’s disease?...
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
Quick links
Infographics
